372 related articles for article (PubMed ID: 21623238)
21. Apelin expression in human non-small cell lung cancer: role in angiogenesis and prognosis.
Berta J; Kenessey I; Dobos J; Tovari J; Klepetko W; Jan Ankersmit H; Hegedus B; Renyi-Vamos F; Varga J; Lorincz Z; Paku S; Ostoros G; Rozsas A; Timar J; Dome B
J Thorac Oncol; 2010 Aug; 5(8):1120-9. PubMed ID: 20581707
[TBL] [Abstract][Full Text] [Related]
22. Prognostic significance of MCM7 expression in the bronchial brushings of patients with non-small cell lung cancer (NSCLC).
Liu YZ; Jiang YY; Hao JJ; Lu SS; Zhang TT; Shang L; Cao J; Song X; Wang BS; Cai Y; Zhan QM; Wang MR
Lung Cancer; 2012 Jul; 77(1):176-82. PubMed ID: 22456526
[TBL] [Abstract][Full Text] [Related]
23. Clinical significance of IGF1R expression in non-small-cell lung cancer.
Nakagawa M; Uramoto H; Oka S; Chikaishi Y; Iwanami T; Shimokawa H; So T; Hanagiri T; Tanaka F
Clin Lung Cancer; 2012 Mar; 13(2):136-42. PubMed ID: 22133293
[TBL] [Abstract][Full Text] [Related]
24. Loss of special AT-rich binding protein 1 expression is a marker of poor survival in lung cancer.
Selinger CI; Cooper WA; Al-Sohaily S; Mladenova DN; Pangon L; Kennedy CW; McCaughan BC; Stirzaker C; Kohonen-Corish MR
J Thorac Oncol; 2011 Jul; 6(7):1179-89. PubMed ID: 21597389
[TBL] [Abstract][Full Text] [Related]
25. Synergistic effect of Bcl-2 and cyclin A2 on adverse recurrence-free survival in stage I non-small cell lung cancer.
Ko E; Kim Y; Cho EY; Han J; Shim YM; Park J; Kim DH
Ann Surg Oncol; 2013 Mar; 20(3):1005-12. PubMed ID: 23115005
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of tumor size in patients with stage III non-small-cell lung cancer: a surveillance, epidemiology, and end results (SEER) survey from 1998 to 2003.
Morgensztern D; Waqar S; Subramanian J; Gao F; Trinkaus K; Govindan R
J Thorac Oncol; 2012 Oct; 7(10):1479-84. PubMed ID: 22982648
[TBL] [Abstract][Full Text] [Related]
27. High TBX2 expression predicts poor prognosis in non-small cell lung cancer.
Zhang Z; Guo Y
Neoplasma; 2014; 61(4):476-80. PubMed ID: 25027744
[TBL] [Abstract][Full Text] [Related]
28. Sex-specific survival advantage with parathyroid hormone-related protein in non-small cell lung carcinoma patients.
Hastings RH; Laux AM; Casillas A; Xu R; Lukas Z; Ernstrom K; Deftos LJ
Clin Cancer Res; 2006 Jan; 12(2):499-506. PubMed ID: 16428492
[TBL] [Abstract][Full Text] [Related]
29. Phosphorylated tubulin adaptor protein CRMP-2 as prognostic marker and candidate therapeutic target for NSCLC.
Oliemuller E; Peláez R; Garasa S; Pajares MJ; Agorreta J; Pío R; Montuenga LM; Teijeira A; Llanos S; Rouzaut A
Int J Cancer; 2013 May; 132(9):1986-95. PubMed ID: 23023514
[TBL] [Abstract][Full Text] [Related]
30. Survival and treatment of non-small cell lung cancer stage I-II treated surgically or with stereotactic body radiotherapy: patient and tumor-specific factors affect the prognosis.
Mokhles S; Nuyttens JJ; Maat AP; Birim Ö; Aerts JG; Bogers AJ; Takkenberg JJ
Ann Surg Oncol; 2015 Jan; 22(1):316-23. PubMed ID: 24962941
[TBL] [Abstract][Full Text] [Related]
31. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent.
Gouyer V; Conti M; Devos P; Zerimech F; Copin MC; Créme E; Wurtz A; Porte H; Huet G
Cancer; 2005 Apr; 103(8):1676-84. PubMed ID: 15754326
[TBL] [Abstract][Full Text] [Related]
32. Prognostic implications of neuroendocrine differentiation and hormone production in patients with Stage I nonsmall cell lung carcinoma.
Pelosi G; Pasini F; Sonzogni A; Maffini F; Maisonneuve P; Iannucci A; Terzi A; De Manzoni G; Bresaola E; Viale G
Cancer; 2003 May; 97(10):2487-97. PubMed ID: 12733148
[TBL] [Abstract][Full Text] [Related]
33. Prognostic impact of COX-2 in non-small cell lung cancer: a comprehensive compartment-specific evaluation of tumor and stromal cell expression.
Mattsson JS; Bergman B; Grinberg M; Edlund K; Marincevic M; Jirström K; Pontén F; Hengstler JG; Rahnenführer J; Karlsson MG; Karlsson C; Helenius G; Botling J; Micke P; Gulyas M
Cancer Lett; 2015 Jan; 356(2 Pt B):837-45. PubMed ID: 25449785
[TBL] [Abstract][Full Text] [Related]
34. Stage III non-small-cell lung cancer: population-based patterns of treatment in British Columbia, Canada.
Vinod SK; Wai E; Alexander C; Tyldesley S; Murray N
J Thorac Oncol; 2012 Jul; 7(7):1155-63. PubMed ID: 22617240
[TBL] [Abstract][Full Text] [Related]
35. The prognostic impact of sex on surgically resected non-small cell lung cancer depends on clinicopathologic characteristics.
Sterlacci W; Tzankov A; Veits L; Oberaigner W; Schmid T; Hilbe W; Fiegl M
Am J Clin Pathol; 2011 Apr; 135(4):611-8. PubMed ID: 21411784
[TBL] [Abstract][Full Text] [Related]
36. Epithelial-Mesenchymal Transition in Non Small-cell Lung Cancer.
Tsoukalas N; Aravantinou-Fatorou E; Tolia M; Giaginis C; Galanopoulos M; Kiakou M; Kostakis ID; Dana E; Vamvakaris I; Korogiannos A; Tsiambas E; Salemis N; Kyrgias G; Karameris A; Theocharis S
Anticancer Res; 2017 Apr; 37(4):1773-1778. PubMed ID: 28373440
[TBL] [Abstract][Full Text] [Related]
37. Prognostic implications of cell cycle-related proteins in primary resectable pathologic N2 nonsmall cell lung cancer.
Mohamed S; Yasufuku K; Hiroshima K; Nakajima T; Yoshida S; Suzuki M; Sekine Y; Shibuya K; Iizasa T; Farouk A; Fujisawa T
Cancer; 2007 Jun; 109(12):2506-14. PubMed ID: 17487846
[TBL] [Abstract][Full Text] [Related]
38. Deregulation of p27 and cyclin D1/D3 control over mitosis is associated with unfavorable prognosis in non-small cell lung cancer, as determined in 405 operated patients.
Sterlacci W; Fiegl M; Hilbe W; Jamnig H; Oberaigner W; Schmid T; Augustin F; Auberger J; Obermann EC; Tzankov A
J Thorac Oncol; 2010 Sep; 5(9):1325-36. PubMed ID: 20631637
[TBL] [Abstract][Full Text] [Related]
39. Biological and prognostic role of acid cysteine proteinase inhibitor (ACPI, cystatin A) in non-small-cell lung cancer.
Leinonen T; Pirinen R; Böhm J; Johansson R; Rinne A; Weber E; Kosma VM
J Clin Pathol; 2007 May; 60(5):515-9. PubMed ID: 16790691
[TBL] [Abstract][Full Text] [Related]
40. Prognostic impact of fibroblast growth factor 2 in non-small cell lung cancer: coexpression with VEGFR-3 and PDGF-B predicts poor survival.
Donnem T; Al-Shibli K; Al-Saad S; Busund LT; Bremnes RM
J Thorac Oncol; 2009 May; 4(5):578-85. PubMed ID: 19318994
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
